Navigation Links
Neurologix Appoints Adrian Adams as Company Chairman and Chief Executive Officer
Date:9/20/2011

negative cash flows from operating activities of approximately $63.0 million and $48.9 million, respectively. Management believes that the Company will continue to incur net losses and cash flow deficiencies from operating activities for the foreseeable future. Because it may take years to develop, test and obtain regulatory approval for a gene-based therapy product before it can be sold, the Company likely will continue to incur significant losses for the foreseeable future. Accordingly, it may never be profitable and, if it does become profitable, it may be unable to sustain profitability.
  • At June 30, 2011, the Company had cash and cash equivalents of approximately $3.5 million. Based on its cash flow projections, the Company will need additional financing to carry out its planned business activities and plan of operations after October 31, 2011 and to repay the promissory notes issued in December 2010 as of said date. Accordingly, there is substantial doubt as to the Company's ability to continue as a going concern. The Company is currently seeking to raise funds, through public or private equity offerings, debt financings or corporate collaboration and licensing arrangements, sufficient to finance its ongoing operations.  The Company does not know whether additional financing will be available when needed, or if available, will be on acceptable or favorable terms to it or its stockholders.
  • The Company will need to conduct future clinical trials for the treatment of Parkinson's disease using the Company's NLX technology. If the trials prove unsuccessful, future operations and the potential for profitability will be materially adversely affected and the business may not succeed.

  • Other factors and assumptions not identified above could also cause the actual results to differ materially from those set forth in the forward-looking statements. Additional information regarding factors which could cause res
    '/>"/>

    SOURCE Neurologix, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related biology technology :

    1. Neurologix Announces Second Quarter 2011 Financial Results
    2. Neurologix Presents One-Year Follow-Up Data From Phase 2 Study of NLX-P101 in Parkinsons Disease at International Neuromodulation Society 10th World Congress
    3. Planet Biopharmaceuticals, Inc. Appoints Theron (Ted) Odlaug, Ph.D. as Executive Chairman
    4. 3-V Biosciences Appoints George W. Kemble, PhD, as Chief Scientific Officer
    5. Creabilis Appoints Dr David Roblin as Chief Medical Officer
    6. MRIGlobal Appoints Richard A. Winegar, Ph.D., as Principal Advisor for Science
    7. Amsterdam Molecular Therapeutics Appoints Dr. Carlos R. Camozzi as Chief Medical Officer
    8. Imagenetix, Inc. Appoints Bill Toomey to Its Board of Directors
    9. Oramed Pharmaceuticals Appoints Dr. Michael Berelowitz as Chairman of Scientific Advisory Board
    10. Crescendo Biologics Appoints Matthew Roe as Chief Business Officer
    11. Synthetic Genomics Inc. Appoints Joseph Mahler as Chief Financial Officer
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:12/17/2014)... (PRWEB) December 17, 2014 Gene ... that it has entered into a technology access ... (ADM) to apply DNA2.0’s proprietary protein engineering technology, ... process. , “We are extremely excited that the ... platform. This proprietary bioengineering technology has now ...
    (Date:12/17/2014)... SOUTH SAN FRANCISCO, Calif. , Dec. 17, ... positive results of a Phase 2 study evaluating ... for the treatment of patients with severe, chronic ... the current standard of care, including topical steroids ... endpoint was percent change in Visual Analog Scale ...
    (Date:12/15/2014)...  GlassesOff Inc. (OTCBB: GLSO) announced today the appointment ... director of the Company,s Board of Directors. ... its CEO until its acquisition by Stanley Black ... Recognized as the inventor of the first Wi-Fi-based Active ... -based RFID solutions focused on improving operational efficiency, safety ...
    (Date:12/13/2014)... (PRWEB) December 12, 2014 Clarassance, a ... announced its new name: Therabron Therapeutics , Inc. ... and bronchioles (a type of structure in the lungs ... company’s mission to develop novel protein therapeutics for the ... directors decided to change the name to mark the ...
    Breaking Biology Technology:ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4AeroScout Founder Joins GlassesOff's Board of Directors 2AeroScout Founder Joins GlassesOff's Board of Directors 3Maryland-based Biotech Company's Path Forward in Treating Respiratory Diseases Sparks Name Change 2
    ... , Iezzi M, Kouri G, Fukuda M, Wollheim CB , ... Ca 2+ -dependent insulin exocytosis. J Cell , ... In a recently published paper in the , ... siRNA target finder and the p Silencer ...
    ... ideal for RT-PCR based gene quantitation, including experiments ... Cells-to-cDNA Kit comes in an , ... cells without RNA isolation in less than 2 hours. By using an , ... RT-PCR can , be carried out ...
    ... by Sapna Chacko , ... treated water , Certified free of endonuclease, exonuclease, , ... sizes to suit all your , experimental needs , ... for RNA isolation and analysis can contribute to experimental , ...
    Cached Biology Technology:Your Data: Use of pSilencer 1.0-U6 siRNA Expression Vector in the Analysis of Synaptotagmin Location and Function 2Your Data: Use of pSilencer 1.0-U6 siRNA Expression Vector in the Analysis of Synaptotagmin Location and Function 3Your Data: Use of pSilencer 1.0-U6 siRNA Expression Vector in the Analysis of Synaptotagmin Location and Function 4Your Data: Detection of Oocyte-specific Gene Expression Using Ambion's Cells-to-cDNA Kit 2Which Water to Use? 2Which Water to Use? 3Which Water to Use? 4Which Water to Use? 5Which Water to Use? 6
    (Date:11/21/2014)... Nov. 20, 2014 C-Labs LLC, a leading ... of Things (IoT), today announced the appointment of ... officer. Previously a strategic advisor to the firm, Mr. ... Mr. Traynor is based out of the C-Labs office ... to Chris Muench , Chief Executive Officer. ...
    (Date:11/18/2014)... 2014 The Parenteral Drug Association (PDA) today confirmed ... speak and at least seven more will participate in the ... Shoreham Hotel in Washington D.C. , Dec. ... significant support from the regulatory agencies in the ... in our effort to help advance the use of metrics ...
    (Date:11/11/2014)... 11, 2014  Forensicon, Inc., a Chicago ... to announce the promotion of Yaniv Schiff ... Forensics. In Schiff,s new role as Director, he will ... digital forensics examiners and provide leadership within the company,s ... http://photos.prnewswire.com/prnh/20141110/157719 Schiff joined Forensicon ...
    Breaking Biology News(10 mins):C-Labs Names Former Microsoft and Bsquare Executive as Chief Operating Officer 2FDA's Janet Woodcock, EMA's Emer Cooke Headline PDA Quality Metrics Conference 2Yaniv Schiff Promoted to Director of Digital Forensics at Forensicon, Inc. 2
    ... one step closer to finding new drugs to fight ... bioservices organisation announced that its fungal collection will be ... one of the world’s largest genetic resource collections of ... penicillin producing isolate. They will be supplying the ...
    ... venture into your garden armed with plants, consider who you ... garden plant isn’t as passive as widely assumed, at least ... plants get fiercely competitive when forced to share their pot ... potted with their siblings. , The study appears today ...
    ... a pathological process, however, an individual’s likelihood of having ... different disease processes present in the brain, according to ... National Institute on Aging (NIA), part of the National ... Disease Center at Rush University Medical Center in Chicago. ...
    Cached Biology News:Could fungal collection hold the key to new life-saving drugs? 2Plants recognize their siblings, biologists discover 2Study finds mix of disease processes at work in brains of most people with dementia 2
    KNP-1 (HES1) Purified Anti-Mouse, Anti-Rat, Anti-Human, Anti-Dog, Anti-Chicken clone 35, Isotype Mouse IgG 1 , 150 µg Consult technical datasheet for details....
    NATIVE RAT OSTEOCALCIN...
    Form: Ready to use Applications: ELISA...
    Goat polyclonal to p27 KIP 1 ( Abpromise for all tested applications). Antigen: Synthetic peptide: C-KRPATDDS STQNK, corresponding to Internal sequence amino acids 153-165 of Human p27 KIP 1 ...
    Biology Products: